Pharmocann Global Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Meir Shimon
Chief executive officer
₪849.1k
Total compensation
| CEO salary percentage | 72.4% |
| CEO tenure | 1.8yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
The Returns On Capital At Pharmocann Global (TLV:PMCN) Don't Inspire Confidence
Mar 30
Should You Use Pharmocann Global's (TLV:PMCN) Statutory Earnings To Analyse It?
Feb 04Pharmocann Global Ltd (TLV:PMCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Dec 31
The Returns At Pharmocann Global (TLV:PMCN) Provide Us With Signs Of What's To Come
Nov 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -₪10m |
| Mar 31 2024 | n/a | n/a | -₪10m |
| Dec 31 2023 | ₪849k | ₪615k | -₪10m |
Compensation vs Market: Meir's total compensation ($USD233.27K) is below average for companies of similar size in the IL market ($USD428.07K).
Compensation vs Earnings: Insufficient data to compare Meir's compensation with company performance.
CEO
Meir Shimon
1.8yrs
Tenure
₪849,055
Compensation
Mr. Meir Shimon is CEO & Director of Pharmocann Global Ltd from March 15, 2023.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | ₪849.06k | no data | |
| Chairman of the Board | no data | ₪589.00k | no data | |
| Director | 5.5yrs | ₪211.00k | no data | |
| External Independent Director | no data | no data | no data | |
| Independent Director | no data | no data | no data | |
| External Independent Director | less than a year | no data | no data |
1.8yrs
Average Tenure
43yo
Average Age
Experienced Board: PMCN-M's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 12:03 |
| End of Day Share Price | 2024/12/22 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharmocann Global Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|